INNOGEN-B (02591) Announces February 2026 Monthly Return with No Change in Share Capital

Bulletin Express

Mar 04

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) released its monthly return for the period ended 28 February 2026, confirming no change in its issued share capital composition. The total authorised share capital amounted to RMB 456.82 million, comprising 420.29 million H shares listed on the Stock Exchange and 36.53 million unlisted shares.

As of the end of February 2026, the number of issued H shares remained at 420.29 million, and the public float requirement of 25.00% was fulfilled. The unlisted shares continued at 36.53 million. There were no outstanding share options, warrants, or convertible securities during the reporting period, and the company had no treasury shares on record.

The return was submitted on 4 March 2026 by the Joint Company Secretary, stating that all disclosure and regulatory obligations had been met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1144978709"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144978709\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144978709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144978709","market":"us","top_or_hot":-1,"title":"INNOGEN-B (02591) Announces February 2026 Monthly Return with No Change in Share Capital","media":"Bulletin Express","content":"<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) released its monthly return for the period ended 28 February 2026, confirming no change in its issued share capital composition. The total authorised share capital amounted to RMB 456.82 million, comprising 420.29 million H shares listed on the Stock Exchange and 36.53 million unlisted shares.</p>\n<p>As of the end of February 2026, the number of issued H shares remained at 420.29 million, and the public float requirement of 25.00% was fulfilled. The unlisted shares continued at 36.53 million. There were no outstanding share options, warrants, or convertible securities during the reporting period, and the company had no treasury shares on record.</p>\n<p>The return was submitted on 4 March 2026 by the Joint Company Secretary, stating that all disclosure and regulatory obligations had been met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Announces February 2026 Monthly Return with No Change in Share Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Announces February 2026 Monthly Return with No Change in Share Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-04 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) released its monthly return for the period ended 28 February 2026, confirming no change in its issued share capital composition. The total authorised share capital amounted to RMB 456.82 million, comprising 420.29 million H shares listed on the Stock Exchange and 36.53 million unlisted shares.</p>\n<p>As of the end of February 2026, the number of issued H shares remained at 420.29 million, and the public float requirement of 25.00% was fulfilled. The unlisted shares continued at 36.53 million. There were no outstanding share options, warrants, or convertible securities during the reporting period, and the company had no treasury shares on record.</p>\n<p>The return was submitted on 4 March 2026 by the Joint Company Secretary, stating that all disclosure and regulatory obligations had been met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1144978709","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144978709","pubTimestamp":1772615937,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) released its monthly return for the period ended 28 February 2026, confirming no change in its issued share capital composition....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"英诺健-B(02591)公布2026年2月股本无变动月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) released its monthly return for the period ended 28 February 2026, confirming no change in its issued share capital composition. The total authorised share capital amounted to RMB 456.82 million, comprising 420.29 million H shares listed on the Stock Exchange and 36.53 million unlisted shares.\nAs of the end of February 2026, the number of issued H shares remained at 420.29 million, and the public float requirement of 25.00% was fulfilled. The unlisted shares continued at 36.53 million. There were no outstanding share options, warrants, or convertible securities during the reporting period, and the company had no treasury shares on record.\nThe return was submitted on 4 March 2026 by the Joint Company Secretary, stating that all disclosure and regulatory obligations had been met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}